OATP-I Activators

Chemical activators of OATP-I can engage in various cellular signaling pathways, leading to its functional activation. Forskolin, by activating adenylyl cyclase, increases the intracellular concentration of cAMP, a secondary messenger that activates protein kinase A (PKA). Active PKA then phosphorylates target proteins, which may include those involved in the regulation and trafficking of OATP-I, leading to its increased activity at the cell surface. Similarly, Glucagon elevates cAMP levels, which also activates PKA, potentially enhancing OATP-I activity. Phorbol 12-myristate 13-acetate (PMA), on the other hand, directly activates protein kinase C (PKC), a kinase that can phosphorylate and thus modulate the activity of various proteins, including transporters like OATP-I. This phosphorylation can lead to an increase in the functional transport capacity of OATP-I. Insulin initiates a signaling cascade that activates the PI3K/AKT pathway, a mechanism that can promote the translocation of transporters, potentially including OATP-I, to the plasma membrane, thereby increasing their functional activity.

In addition, ionomycin, by raising intracellular calcium levels, can activate calcium-dependent PKC isoforms, which may lead to the phosphorylation and subsequent activation of OATP-I. Sodium fluoride, a known activator of phosphorylase kinase, could enhance the activation of PKA and PKC, indirectly contributing to the activation of OATP-I. Okadaic acid, by inhibiting protein phosphatases, prevents dephosphorylation, potentially leading to a sustained activation state of OATP-I. Growth factors such as EGF, through its receptor, initiate kinase signaling pathways that can result in the activation of downstream proteins, including OATP-I. Nitric oxide donors, through the release of nitric oxide, activate soluble guanylyl cyclase, increasing cGMP levels, and activating protein kinase G (PKG), which might influence OATP-I activity. Cholera toxin, by permanently activating Gαs, can lead to increased cAMP levels and prolonged PKA activation, which may indirectly enhance OATP-I's activity. Finally, cAMP analogs, such as 8-Br-cAMP, directly stimulate PKA, leading to a cascade of events that could include the phosphorylation and activation of OATP-I, facilitating its role in cellular transport.